文献速递肝病

奥贝胆酸改善原发性胆汁性胆管炎患者的肝脏胆汁酸排泄

Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
PubMed 文献 · J Hepatol · 2020-07-25

8例对熊去氧胆酸应答不足的原发性胆汁性胆管炎患者参与双盲、安慰剂对照交叉研究,继续熊去氧胆酸并随机接受安慰剂和奥贝胆酸各3个月。奥贝胆酸较安慰剂使肝脏血液灌注中位数增加11%(p=0.045),11C-CSar从血液进入肝细胞单向摄取清除率中位数增加11%(p=0.01),从肝细胞分泌至胆管小管的速率常数中位数增加73%(p=0.03),肝细胞停留时间中位数降低30%(p=0.01),从组中位数11分钟降至8分钟。

要点

  • 奥贝胆酸较安慰剂使肝脏血液灌注中位数增加11%(p=0.045)。
  • 奥贝胆酸较安慰剂使11C-CSar肝细胞摄取清除率中位数增加11%(p=0.01)。
  • 奥贝胆酸较安慰剂使11C-CSar胆管小管分泌速率常数中位数增加73%(p=0.03),肝细胞停留时间降低30%(p=0.01)。

核心结论

  • 在熊去氧胆酸治疗的原发性胆汁性胆管炎患者中,与安慰剂相比,奥贝胆酸增加结合胆汁酸示踪剂11C-CSar从肝细胞到胆管小管的肝脏转运。
  • 奥贝胆酸减少肝细胞暴露于潜在细胞毒性胆汁酸的时间。

研究设计与样本

  • 双盲、安慰剂对照交叉研究,纳入8例碱性磷酸酶≥正常上限1.5倍且正在接受熊去氧胆酸治疗的原发性胆汁性胆管炎患者。
  • 患者继续熊去氧胆酸,随机顺序接受安慰剂和奥贝胆酸各3个月交叉治疗,期间间隔1个月无研究药物洗脱期。
  • 每个治疗期后采用结合胆汁酸示踪剂[N-甲基-11C]胆酰肌氨酸(11C-CSar)的肝脏正电子发射断层扫描测定血液、肝细胞、胆管小管和胆管间转运速率常数;采用吲哚菁绿输注和Fick原理测定肝脏血液灌注。

主要发现

  • 与安慰剂相比,奥贝胆酸使肝脏血液灌注中位数增加11%(p=0.045)。
  • 与安慰剂相比,奥贝胆酸使11C-CSar从血液进入肝细胞的单向摄取清除率中位数增加11%(p=0.01)。
  • 与安慰剂相比,奥贝胆酸使11C-CSar从肝细胞分泌至胆管小管的速率常数中位数增加73%(p=0.03)。
  • 与安慰剂相比,奥贝胆酸使11C-CSar肝细胞停留时间中位数降低30%(p=0.01),从组中位数11分钟降至8分钟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Obeticholic acid (OCA) is an agonist of the nuclear bile acid receptor farnesoid X receptor, which regulates hepatic bile acid metabolism. We tested whether OCA treatment would influence hepatic transport of conjugated bile acids in patients with primary biliary cholangitis (PBC) who responded inadequately to treatment with ursodeoxycholic acid (UDCA). METHODS: Eight UDCA-treated patients with PBC with alkaline phosphatase ≥1.5 times the upper limit of normal range participated in a double-blind, placebo-controlled study. While continuing on UDCA, the patients were randomised to two 3-month crossover treatment periods with placebo and OCA, in random order, separated by a 1-month washout period without study treatment. After each of the two treatment periods, we determined rate constants for transport of conjugated bile acids between blood, hepatocytes, biliary canaliculi, and bile ducts by positron emission tomography of the liver using the conjugated bile acid tracer [N-methyl-11C]cholylsarcosine (11C-CSar). The hepatic blood perfusion was measured using infusion of indocyanine green and Fick's principle. RESULTS: Compared with placebo, OCA increased hepatic blood perfusion by a median of 11% (p = 0.045), the unidirectional uptake clearance of 11C-CSar from blood into hepatocytes by a median of 11% (p = 0.01), and the rate constant for secretion of 11C-CSar from hepatocytes into biliary canaliculi by a median of 73% (p = 0.03). This resulted in an OCA-induced decrease in the hepatocyte residence time of 11C-CSar by a median of 30% (p = 0.01), from group median 11 min to 8 min. CONCLUSIONS: This study of UDCA-treated patients with PBC showed that, compared with placebo, OCA increased the hepatic transport of the conjugated bile acid tracer 11C-CSar, and thus endogenous conjugated bile acids, from hepatocytes into biliary canaliculi. As a result, OCA reduced the time hepatocytes are exposed to potentially cytotoxic bile acids. LAY SUMMARY: Primary biliary cholangitis is a chronic liver disease in which the small bile ducts are progressively destroyed. We tested whether the treatment with obeticholic acid (OCA) would improve liver excretion of bile acids compared with placebo in 8 patients with primary biliary cholangitis. A special scanning technique (PET scan) showed that OCA increased the transport of bile acids from blood to bile. OCA thereby reduced the time that potentially toxic bile acids reside in the liver by approximately one-third.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kjærgaard K, Frisch K, Sørensen M, et al. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis. J Hepatol. 2020. PMID: 32717289. doi:10.1016/j.jhep.2020.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。